EXO-OVA-mAb presented stronger ability of activating T cells than others and increased the CTLs/Treg ratio within the tumor site, and this phenomenon may be attributed to the crucial role of anti-CTLA-4 antibody. The gene discussed is CTLA4; the disease is neoplasm.